ArticleChemMedChem2026
Iso- and Benzisothiazolinone Inhibitors of Monoacylglycerol Lipase: Exploring On-Target Activity Through Scaffold Decoration and In Situ Warhead Generation.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Monoacylglycerol lipase (MGL) is an intracellular serine hydrolase that regulates endocannabinoid signaling by hydrolyzing 2-arachidonoylglycerol (2-AG), thereby controlling cannabinoid receptor activity and related physiological processes. Targeting MGL through allosteric mechanisms is a promising strategy to modulate 2-AG levels while avoiding limitations associated with active site-directed inhibitors. In this study, we aimed to develop selective MGL inhibitors based on isothiazolinone (ITZ) and benzisothiazolinone (BTZ) scaffolds that covalently target the regulatory cysteine residues Cys201 and Cys208 forming disulfide adducts. Two complementary approaches were explored. First, a mechanism-based strategy was designed to exploit MGL-mediated hydrolysis of O-substituted (benz)isothiazol-3-ol derivatives, enabling localized release of the reactive warhead in proximity to the target cysteines. Second, to enhance molecular recognition, tailored substituents were introduced on the BTZ scaffold to promote selective interactions with residues surrounding the allosteric site. Although several compounds displayed nanomolar inhibitory activity, structure-activity relationship analysis indicated that inhibitory potency is primarily driven by intrinsic warhead reactivity rather than specific protein-ligand interactions. Overall, these findings highlight both the potential and the challenges of developing selective covalent allosteric MGL inhibitors, emphasizing the need for strategies that better balance reactivity and molecular recognition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.